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ABSTRACT
Variants in AS3MT, the gene encoding arsenic (þ3 oxidation state) methyltranserase, have been shown to influence
patterns of inorganic arsenic (iAs) metabolism. Several studies have suggested that capacity to metabolize iAs may vary
depending on levels of iAs exposure. However, it is not known whether the influence of variants in AS3MT on iAs
metabolism also vary by level of exposure. We investigated, in a population of Mexican adults exposed to drinking water As,
whether associations between 7 candidate variants in AS3MT and urinary iAs metabolites were consistent with prior
studies, and whether these associations varied depending on the level of exposure. Overall, associations between urinary
iAs metabolites and AS3MT variants were consistent with the literature. Referent genotypes, defined as the genotype
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previously associated with a higher percentage of urinary dimethylated As (DMAs%), were associated with significant
increases in the DMAs% and ratio of DMAs to monomethylated As (MAs), and significant reductions in MAs% and iAs%. For
3 variants, associations between genotypes and iAs metabolism were significantly stronger among subjects exposed to
water As>50 versus50 ppb (water As X genotype interaction P< .05). In contrast, for 1 variant (rs17881215), associations
were significantly stronger at exposures 50 ppb. Results suggest that iAs exposure may influence the extent to which
several AS3MT variants affect iAs metabolism. The variants most strongly associated with iAs metabolism—and perhaps
with susceptibility to iAs-associated disease—may vary in settings with exposure level.
Key words: Arsenic (þ3 oxidation state) methyltranserase polymorphism; arsenic; drinking water; urinary arsenic; arsenic
metabolites; methylation capacity.
Chronic exposure to inorganic arsenic (iAs) has been associated
with increased risk of several types of cancer, with a substantial
literature suggesting iAs exposure may also be associated with
other health outcomes, including cardiovascular diseases and
diabetes (Iarc Working Group on the Evaluation of Carcinogenic
Risks to Humans, 2012; Maull et al., 2012; Moon et al., 2012; Sung
et al., 2015). There are multiple sources of exposure to iAs, in-
cluding contaminated drinking water, food, soil, and air, as well
as occupational settings (Iarc Working Group on the Evaluation
of Carcinogenic Risks to Humans, 2012). Contaminated drinking
water is a common source of high exposure, and is a wide-
spread public health problem, estimated to affect around 140
million people worldwide (Iarc Working Group on the
Evaluation of Carcinogenic Risks to Humans, 2012; Smith et al.,
2000). There is growing evidence that, along with levels of expo-
sure to iAs, inter-individual variation in the capacity to metabo-
lize iAs is an important determinant of toxicity, and thus of
health risks related to this exposure (Pierce et al., 2013; Sun et al.,
2007). Using measures of proportions of iAs metabolites in
urine, which have been postulated to reflect capacity to metabo-
lize iAs, numerous studies suggest that individual variation in
patterns of iAs metabolism may influence susceptibility to ad-
verse health outcomes among subjects exposed to iAs in drink-
ing water (Chen et al., 2013; Mendez et al., 2015), or may be
directly associated with health risks (Del Razo et al., 2011; Huang
et al., 2007; Kuo et al., 2015; Lindberg et al., 2008; Sun et al., 2007).
Although the indicators of iAs metabolism most strongly re-
lated to risk have varied, associations between measures of iAs
metabolism and health risks have been reported in settings
with widely varying levels of iAs exposure (Chen et al., 2005,
2013; Del Razo et al., 2011; Engstrom et al., 2015; Lindberg et al.,
2008; Mendez et al., 2015).
In humans, the primary pathway for metabolism of iAs in-
volves sequential methylation to form monomethylated As
(MAs) and dimethylated As (DMAs) metabolites, which are ex-
creted in the urine (Thomas et al., 2007). Higher percentages of
total urinary As represented by DMAs (DMAs%), and lower per-
centages of MAs or the unmethylated iAs (MAs% and iAs%, re-
spectively) in urine have been hypothesized to be indicators of
higher capacity to metabolize iAs (Thomas et al., 2007; Tseng,
2007; Vahter, 2002). The ratios of MAs to iAs (MAs/iAs) and of
DMAs to MAs (DMAs/MAs) in urine have also been widely used
as indicators of capacity for the first and second methylation
steps. However, the measures of iAs metabolism most predic-
tive of increased health risks remain to be established, given
the conflicting associations reported in recent studies (Chen
et al., 2013; Del Razo et al., 2011; Mendez et al., 2015; Nizam et al.,
2013; Thomas et al., 2007).
Arsenic (þ3 oxidation state) methyltrasferase (AS3MT) is a
key enzyme in the pathway for the methylation of iAs, and
variants in the AS3MT have been shown to be associated with
inter-individual differences in iAs metabolism (Antonelli et al.,
2014; Fu et al., 2014; Gribble et al., 2015; Pierce et al., 2012;
Schlebusch et al., 2015; Wood et al., 2006). Previous studies have
linked polymorphic sites in this gene to significant differences
in urinary measures of iAs metabolism in various populations
(Antonelli et al., 2014; Fu et al., 2014; Gao et al., 2015; Gribble et al.,
2015; Pierce et al., 2012; Wood et al., 2006). It has been suggested
that iAs exposure level may modify iAs metabolism, as reflected
by changes in urinary As methylation profiles, with a shift in
the proportions of urinary metabolites among persons exposed
to levels approximately>50 versus50ppb (Kile et al., 2009;
Lindberg et al., 2008; Pierce et al., 2013; Schlebusch et al., 2015).
We have previously reported based on laboratory experiments
that levels and proportions of the methylated products, includ-
ing DMAs/MAs ratio, differ between recombinant variants of hu-
man AS3MT and depend on the substrate concentration (Ding
et al., 2012). However, to our knowledge, no population study
has formally explored to what extent associations between
AS3MT variants and measures of iAs metabolism may vary de-
pending on levels of iAs exposure. Such heterogeneity, if pre-
sent, could lead to inconsistencies across populations with
varying iAs exposure in the extent to which genetic variants ei-
ther relate to measures of iAs metabolism, or modify health
risks associated with environmental iAs exposure.
The aims of this study were to examine the consistency of
previously established associations between multiple AS3MT
variants and the profiles of urinary iAs metabolites in a popula-
tion with substantial variability in exposure, and to assess evi-
dence of heterogeneity in the magnitude of these associations




Participants were originally recruited for a cross-sectional study
on the association of iAs exposure with prevalence of diabetes
mellitus in Chihuahua, Mexico, which has been described previ-
ously (Mendez et al., 2015). Briefly, in the parent study, a total of
1160 adults were recruited with a minimum of 5-year uninter-
rupted residency in the area. Pregnant women, subjects with uri-
nary tract infection, and individuals with potential occupational
exposure to iAs (eg, those working with pesticides or in mines or
smelters) were excluded since these conditions affect the urinary
profiles of iAs metabolites(Cocker et al., 2006; Colin-Torres et al.,
2014; Gardner et al., 2012; Li et al., 2016; Loh et al., 2016).
Participants provided samples of household drinking water and
spot urine samples in which As metabolites were measured, and
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interviewer-administered questionnaires were used to collect a
wide array of information on factors including health status
(including diagnosed diabetes), use of medications, smoking, use
of alcohol. Physical exams included an oral glucose tolerance test
(OGTT) for detecting undiagnosed diabetes, as well as measures
of weight, height, body mass index (BMI), waist and hip circum-
ferences, blood pressure, and skin lesions associated with iAs
exposure. For use in sensitivity analyses exploring effects of dia-
betes, subjects were classified as having diabetes based on fast-
ing plasma glucose  126 mg/dl or 2-h post OGTT glucose
(2 HPG 200 mg/dl), or on self-reported diagnosis or use of diabe-
tes medication (Kerner et al., 2014; World Health Organization,
2006). All subjects provided signed informed consent, and the
study was approved by the Institutional Review Boards of UNC-
Chapel Hill and the Centro de Investigacion y de Estudios
Avanzados of the Instituto Polite´cnico Nacional in Mexico City.
Measurements of water and urinary As
The analyses of As in water and urines were described in detail
in the parent study (Mendez et al., 2015). Drinking water was col-
lected in subjects’ homes, and the concentration of iAs in these
water samples was measured by hydride generation (HG)-cryo-
trapping (CT)-atomic absorption spectrometry (AAS)
(Hernandez-Zavala et al., 2008). Spot urine samples were col-
lected during morning medical exams as described previously
(Currier et al., 2014). Concentrations of iAs, MAs and DMAs in
spot urine were measured by HG-CT-AAS. Certified standard
reference materials (SRMs) from the inter-laboratory compari-
son program in Quebec and the SRM 2669 (Arsenic Species in
Frozen Human Urine) from National Institute of Standards and
Technology were used as quality controls.
The limit of detection (LOD) for iAs in water as well As spe-
cies in urine was 0.01 lg As/l. Concentrations of water iAs and
urinary As species which were below LOD (1.9% for water iAs,
1.6% for urinary iAs) were imputed at LOD/2. Total speciated As
in urine (tAs) was calculated as sum of the iAs, MAs and DMAs.
iAs metabolism was characterized using measures recom-
mended in the literature (Thomas et al., 2001; Vahter and
Concha, 2001), namely percentages of each iAs metabolite
(DMAs%, MAs%, iAs%), as well as the ratios of MAs/iAs (also
known as the primary methylation index) and DMAs/MAs (the
secondary methylation index) in urine.
Genotyping
DNA was isolated from venous blood collected in the OGTT
using the QIAamp DNA Blood Mini Kit (Qiagen) according to the
manufacturer’s protocol. We reviewed the available literature to
look for candidate AS3MT variants associated with urinary As
profiles. Nine AS3MT variants linked to differences in iAs
metabolism or susceptibility to iAs toxicity were identified for
analysis in this study based on literature published through
April 2011 (Agusa et al., 2009; Chung et al., 2009a,b; Engstrom
et al., 2011; Hernandez-Zavala et al., 2008; Hwang et al., 2010;
Lindberg et al., 2007; Sampayo-Reyes et al., 2010; Schlawicke
Engstrom et al., 2007; Thomas et al., 2001; Valenzuela et al., 2009;
Wood et al., 2006). These AS3MT variants included 8 single
nucleotide polymorphisms (SNPs), rs35232887 (Arg173Trp),
rs34556438 (Thr306lle), rs11191439 (Met287Thr), rs17881215
(G4965C), rs3740393 (G12390C), rs3740390 (C14215T), rs11191453
(T35587C), rs10748835 (G35991A), and 3 variable number of tan-
dem repeats (VNTR) variants, AB, A2B, and A3B. The AS3MT var-
iants were analyzed either in the Mammalian Genotyping Core
(UNC, Chapel Hill, North Carolina, USA) or in our laboratory
(VNTR and rs17181215), using predesigned or custom TaqMan
assays (Applied Biosystems, Carlsbad, CA, USA). The ABI Dual
384-Well GeneAmp PCR System 9700 and ABI PRISM 7900HT
Sequence Detection System from Applied Biosystems was used
for genotyping and the ABI SDS software for data analysis.
VNTR variants and rs17881215 were identified by sequencing a
PCR-amplified promoter region.
Due to funding constraints, samples for a random subset of
approximately half the subjects in the full sample were sent to
the Mammalian Genotyping Core (N¼ 543). A random sample
was also analyzed for rs17881215 and VNTR in our laboratory.
Due to genotyping failure, the analysis sample available for
each variant measured in the core facility varied in size from
N¼ 500 (for rs10748835) to N¼ 506 (for rs3740393), with N¼ 715
available for rs17881215 and VNTR. 772 subjects had data on at
least 1 candidate genetic marker along with measures of water
As, iAs metabolism, age and gender. In addition to our primary
analyses in the maximum sample with available data for each
variant, we analyzed associations in a sample limited to sub-
jects with data available for all candidate variants (N¼ 483) to
confirm that effects were not affected by varied sample size;
results were not meaningfully different (Supplementary
Appendix Table 1).
Statistical analysis
We estimated associations between candidate variants in
AS3MT and each measure of iAs metabolism described above. In
all analyses, we defined the variant previously reported to be
associated with a higher DMAs% as the referent genotype in
order to facilitate comparisons with existing literature.
Genotype frequencies were estimated and tested for departure
from Hardy-Weinberg equilibrium by calculating pairwise r2
coefficients between variants.
To determine whether candidate AS3MT variants were
related to biomarker estimates of overall iAs exposure versus
to measures of iAs metabolism, we first compared median (25th
and 75th percentile) tAs, as well as each indicator of iAs metab-
olism, across allelic variants. Medians were used rather than
means given the highly non-normal distribution of tAs
(Shapiro-Wilk P< .01). The non-parametric Kruskall-Wallis test
was used to identify statistically significant differences in each
As measure across genotypes for each polymorphism. For all
analyses, P< .10 was used a priori to define marginal signifi-
cance and P < .05 to define significance, given the moderate
sample size. We further evaluated associations between AS3MT
genotypes and indicators of metabolism using multiple linear
regression models adjusting for age and gender, which are
known to influence iAs metabolism (Lindberg et al., 2007, 2008;
Loffredo et al., 2003; Tseng, 2009). Coefficients from these mod-
els estimated the mean differences in each measure of iAs
metabolism among different genotypes of each variant, adjust-
ing for age and sex.
Next, we explored whether associations between AS3MT var-
iants and iAs metabolism appeared to vary depending on levels
of exposure. To identify AS3MT variants for which associations
with measures of iAs metabolism differed significantly with
changes in the concentration of drinking water As, we tested the
significance of polymorphism  water As interactions in age-
and sex-adjusted linear regression models using global F tests.
Based on previous literature, interactions were tested defining
high versus low water As exposure with a cutoff of 50 ppb, close
to the sample median of 48.64 ppb. Age- and sex-adjusted models
114 | TOXICOLOGICAL SCIENCES, 2016, Vol. 153, No. 1
were also run stratified by higher versus lower water As to com-
pare the magnitude of associations between AS3MT variants and
measures of iAs metabolism among individuals more versus less
exposed, regardless of the significance of interactions.
In addition to sensitivity analyses to evaluate the influence
of varying sample size described above, we compared the asso-
ciations between urinary As profiles and AS3MT variants before
and after adjusting for or excluding persons with diabetes;
results did not differ meaningfully (Supplementary Appendix
Table 2). Additionally, because numerous epidemiological stud-
ies have shown that BMI may influence the metabolism of iAs
(Gomez-Rubio et al., 2011; Grashow et al., 2014; Gribble et al.,
2013; Su et al., 2012), we evaluated the impact of adjusting for
BMI; again, results did not differ meaningfully (data not shown).
Adjusting for self-reported parental race-/ethnicity (Hispanic 93.
5%, Amerindian/indigeneous 2.9%, white 3.3%, and other 0.4%)
did not affect our findings (not shown). Similarly, additionally
adjusting for either total water As or urinary tAs had no mean-
ingful effect (data not shown). Statistical analysis was per-
formed using STATA version 13 (Stata Corporation, College
Station, Texas) except Global F test for the polymorphism 
water As interactions, which was performed with PROC GLM in
SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Characteristics of the Population and AS3MT Genotype
Frequencies
After excluding subjects with missing data on urinary As species,
age, or gender (N¼ 42), there were 772 individuals (520 females,
252 males) with available information on at least 1 candidate
variant. Exposure to water As varied substantially, with a
median (25–75th percentile) of 48.6 (37.1–74.1) ppb and range of
0.01–419.77 ppb. Of the 9 initial candidate AS3MT variants, 2 SNPs
(rs35232887 and rs34556438) had a very low frequency (N < 5) for
the non-wildtype genotypes and were not used for further analy-
sis. Genotype frequencies varied substantially for all other var-
iants (Table 1). Three pairs of SNPs—rs11191439 and rs17881215,
rs3740393 and rs3740390, rs3740390 and rs11191453—were in
linkage disequilibrium with r2>0.8. The referent genotype—
which we defined as the genotype associated with a higher
DMAs% in previously published studies—corresponded to the
wildtype (based on global genotype frequency reports from
National Center for Biotechnology Information) for only 2 SNPs
(rs11191439 and rs17881215, highly correlated with each other)
(Table 1). For rs11191453, since there was no observation in our
sample with the homozygous variant (CC) previously associated
with the highest DMAs%, we used the heterozygous variant (TC)
as the referent. For VNTR, as only N¼ 1 subject had the true refer-
ent genotype A3B, we defined A2B, which was also associated
with a higher DMAs% (Fu et al., 2014; Wood et al., 2006), as the
referent. A3B was excluded from further analyses due to low fre-
quency (N¼ 1).
Urinary Measures of Arsenic Metabolism Varied
Substantially With Variants
Table 1 also shows the median (25th and 75th percentile) of
each measure of iAs metabolism—DMAs%, MAs%, iAs%, DMAs/
MAs, and MAs/iAs—overall and stratified by genotypes of each
AS3MT variant. Values for the percentages and ratios of urinary
metabolites were consistent with the full study population
(Mendez et al., 2015). The median (25th and 75th percentiles) for
tAs, DMAs%, MAs%, iAs%, DMAs/MAs, and MAs/iAs were 62.9
mg/l (34.2, and 108.4 mg/l), 76.9% (71.3%, 81.4%), 13.9% (10.9%,
17.4%), 8.8% (6.3%, 12.2%), 5.5 (4.2, 7.4), and 1.6 (1.2, 2.1),
TABLE 1. Urinary As Profiles of Arsenic Metabolites Overall and by AS3MT Variants (Median and 25 and 75th Percentiles)
N % tAs DMAs% MAs% Unmethylated iAs% DMAs/MAs Ratio MAs/iAs Ratio
p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75) p50 (p25, p75)
All subjects 772 62.9 (34.2, 108.4) 76.9 (71.3. 81.4) 13.9 (10.9,17.4) 8.8 (6.3, 12.2) 5.5 (4.2, 7.4) 1.6 (1.2, 2.1)
By AS3MT variant:
rs11191439a dTT 412 82 59.5 (31.3, 105.5) 77.3** (71.7, 81.8) 13.5** (10.8, 16.7) 8.9 (6.1, 12.4) 5.7** (4.4, 7.6) 1.5 (1.1, 2.1)
TC 86 17 52.5 (30.4, 99.7) 74.9 (66.5, 79.0) 15.8 (13.0, 20.0) 9.8 (6.3, 14.5) 4.7 (3.3, 6.0) 1.8 (1.2, 2.5)
CC 3 1 64.8 (26.6, 151.0) 65.6 (59.2, 73.8) 19.7 (13.9, 27.8) 13.0 (12.2, 14.7) 3.3 (2.1, 5.3) 1.3 (1.1, 2.1)
rs17881215a dGG 579 81 61.4 (33.1, 107.4) 77.6** (72.8, 82.5) 13.4** (10.7, 16.6) 8.6 (6.1, 11.6) 5.8** (4.4, 7.6) 1.6 (1.2, 2.1)
GC 124 17 67.5 (38.0, 112.8) 74.9 (69.0, 80.5) 15.1 (12.8, 19.2) 8.8 (6.7, 13.9) 4.9 (3.6, 6.3) 1.6 (1.2, 2.3)
CC 12 2 45.2 (34.3, 82.4) 73.9 (65.3, 78.7) 19.8 (12.6, 21.6) 11.2 (5.0, 13.1) 3.7 (3.0, 6.2) 1.8 (1.3, 3.0)
rs3740393b GG 280 55 59.0 (30.9, 97.4) 75.3** (69.3, 79.6) 14.7** (11.7, 18.9) 9.9** (7.1, 13.1) 5.1** (3.8, 6.8) 1.6 (1.2, 2.1)
GC 200 40 57.2 (30.6, 107.6) 78.6 (72.9, 83.3) 13.0 (10.8, 16.0) 8.3 (5.4, 12.0) 5.8 (4.6, 7.6) 1.6 (1.1, 2.3)
dCC 26 5 72.6 (46.5, 125.0) 80.7 (74.0, 84.4) 12.0 (9.4, 15.0) 9.2 (4.3, 12.0) 6.7 (5.3, 9.0) 1.2 (1.0, 1.8)
rs3740390a,b,c CC 293 58 59.9 (32.4, 99.5) 75.5** (69.4, 79.7) 14.5** (11.8, 18.8) 10.0** (7.1, 13.3) 5.3** (3.8, 6.8) 1.6 (1.1, 2.1)
CT 192 38 56.6 (30.1, 105.6) 78.7 (73.5, 83.4) 12.8 (10.5, 15.9) 8.1 (5.4, 11.9) 6.2 (4.7, 7.8) 1.6 (1.1, 2.3)
dTT 20 4 71.3 (36.9, 119.2) 80.3 (70.2, 86.0) 12.6 (9.0, 15.3) 7.9 (4.4, 14.8) 6.3 (4.7, 9.5) 1.2 (0.9, 1.7)
rs11191453c TT 290 58 59.7 (32.4, 99.5) 75.3** (69.2, 79.7) 14.6** (11.8, 18.9) 10.0** (7.1, 13.4) 5.2** (3.7, 6.8) 1.6 (1.2, 2.1)
dTC 212 42 57.9 (30.1, 107.6) 78.8 (73.4, 83.5) 12.8 (10.3, 15.9) 8.1 (5.3, 12.0) 6.2 (4.7, 8.0) 1.6 (1.1, 2.3)
rs10748835 GG 151 30 60.5 (33.1, 99.5) 76.0* (70.1, 80.2) 14.5 (12.0,18.1) 9.5 (7.1, 12.9) 5.4* (3.9, 6.6) 1.5 (1.1, 2.1)
GA 251 50 57.2 (29.4, 104.3) 76.7 (70.3, 81.3) 13.7 (10.8, 17.4) 9.0 (6.1, 12.9) 5.5 (4.1, 7.6) 1.6 (1.1, 2.1)
dAA 98 20 64.8 (32.0, 112.6) 78.5 (73.8, 83.5) 13.7 (10.3, 15.9) 8.3 (5.1, 11.7) 5.7 (4.6, 7.7) 1.6 (1.1, 2.2)
VNTR AB 587 82 61.5 (33.2, 112.0) 76.9* (70.9, 81.5) 13.9 (11.0, 17.4) 8.7 (6.2, 12.3) 5.5 (4.1, 7.3) 1.6 (1.2, 2.1)
dA2B 127 18 60.5 (34.2, 92.6) 77.9 (73.8, 82.1) 13.6 (10.6, 16.1) 8.3 (6.3, 10.5) 5.6 (4.6, 7.9) 1.6 (1.2, 2.2)
a,b,c,The pairs of variants shown were in linkage disequilibrium with r2>0.8.
dIdentifies the referent genotype, defined as the genotype associated in previous literature with a higher DMAs%.
*P< .10,
**P<0.05 for Kruskall wallis test for differences in urinary As metabolites among different genotypes of the AS3MT variants. Medians bolded when the Kruskall Wallis
test reached significance (P < .10).
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respectively. Water As was significantly positively correlated
with urinary tAs (Spearman’s R ¼ 0.23, P < 0.01).
In descriptive analysis, no significant difference in tAs
was observed across genotypes for any of the 7 candidate variants
(P > 0.10; Table 1). Descriptive analyses also showed that consis-
tent with prior literature, the referent genotype was associated
with increases in the DMAs% for all 7 candidate markers. These
differences were significant (P < .05) for 5 variants, and marginally
significant for 2 (VNTR and rs10748835, P < .10). The 5 variants
associated with significant increases in the DMAs% were also asso-
ciated with significant reductions in the MAs% (P < 0.05); VNTR
and rs10748835 were associated with small but non-significant
reductions in this measure. Similarly, the DMAs/MAs ratio was sig-
nificantly higher among participants with the referent genotype
for 6 variants, the exception being VNTR. There was a reduction in
iAs% observed for the referent genotypes for 6 of the candidate
markers examined, although differences were at least of margin-
ally significance for only 3 variants. The exception to this pattern,
rs3740393, showed lower iAs% for the heterozygous (GC) instead of
referent homozygous (CC) genotype. In contrast to the patterns
observed for all other measures of iAs metabolism, there were no
clear pattern and no significant differences in the MAs/iAs ratio
across genotypes in any of the candidate variants.
Adjusted mean differences in urinary measures of iAs
metabolism associated with having polymorphisms other than
the referent genotypes are shown in Table 2, based on multi-
variable linear models adjusted for age and gender. Results
were similar to descriptive analyses. Having non-referent geno-
types was associated with significant (P< .05) decreases in the
DMAs% for at least one genotype in all 7 variants, significant
increases in the MAs% for 5 variants, and marginally significant
increases (P< .10) in the MAs% for rs10748835 and VNTR.
Excluding some genotypes with very small cell sizes (N < 5), the
5 SNPs significantly associated with these measures of iAs
metabolism (rs3740390 and 2 correlated SNPs rs3740393 and
rs11191453; rs17881215 and the correlated SNP rs11191439) were
associated with the largest adjusted mean differences in both
DMAs% (from 3.360.7 to 4.662.2%) and MAs% (from 1.860.5 to
3.961.4%), with smaller differences associated with polymor-
phisms in rs10748835 and VNTR.
Significant differences in measures of iAs metabolism
associated with genetic polymorphisms were most notable for
the DMAs/MAs ratio. When compared with the referent geno-
type, all other genotypes in each variant were associated with
at least marginally significant (P< .10) differences in DMAs/
MAs with only 2 exceptions: the homozygous variant of
rs11191439, for which the cell size was small (N¼ 3), and poly-
morphisms in VNTR, for which the association was null. The
magnitude of association with DMAs/MAs was strongest—
a>2-unit change—for variants in rs3740393 and the correlated
SNP rs3740390, with the weakest associations—of about half
this magnitude—for rs10748835. Like the descriptive analyses,
few variants (N¼ 3) were significantly associated with the
iAs%, and none with the MAs/iAs ratio, after multivariable
adjustment.
Associations Between AS3MT Variants and Urinary
Measures of iAs Metabolism Among Subjects With
Higher Versus Lower Exposure to Drinking Water As
There were interactions between elevated (>50 ppb) exposure to
water As and several genetic variants, suggesting that the
degree to which genotype in these variants influence patterns of
iAs metabolism may vary with increasing exposure. Interactions
were significant primarily for the DMAs/MAs ratio (P < .05 for 3
variants: the correlated SNPS rs3740390 and rs3740393, as well
as rs10748835; Figure 1C, Supplementary Appendix Table 3).
There were also marginal significant (P< .10) interactions
between exposure level and one variant (rs17881215) for the
DMAs% and MAs%.
As shown in Figure 1C, the decline in the DMAs/MAs ratio
associated with having genotypes other than the referent was
considerably as well as significantly larger among more versus
less highly exposed individuals for 3 SNPs: rs3740390, the corre-
lated SNP rs3740393, and rs10748835 (see also Supplementary
Appendix Table 4). In the sample as a whole, the magnitude
of associations with the DMA/MAs ratio was strongest for the
first 2 SNPs. However, except for the null relationship with
VNTR, this last SNP—rs10748835—was the variant most weakly
associated with the DMAs/MAs in the overall sample. Though
TABLE 2. Adjusted Associations Between A S3MT Variants and Urinary Profiles of Arsenic Metabolitesa
Dimethylated
Arsenic % (DMAs%)
MAs% Unmethylated iAs% DMAs/MAs Ratio MAs/iAs Ratio
Polymorphism N
Coefficient (SE) P Coefficient (SE) P Coefficient (SE) P Coefficient (SE) P Coefficient (SE) P
rs11191439b (ref TT, N¼412) TC 86 23.5 (1.0) .00** 2.3 (0.6) .00** 1.2 (0.6) .04** 21.2 (0.4) .00** 1.4 (1.2) .23
CC 3 29.1 (4.7) .05* 6.5 (3.1) .04** 2.7 (2.9) .36 2.6 (1.8) .15 1.6 (5.8) .79
rs17881215b (ref GG, N¼579) GC 124 23.3 (0.8) .00** 1.9 (0.5) .00** 1.4 (0.5) .00** 21.1 (0.3) .00** 0.2 (1.5) .92
CC 12 24.6 (2.2) .04** 3.9 (1.4) .01** 0.7 (1.4) .63 21.6 (0.9) .06* 1.5 (4.3) .72
rs3740393c (ref CC, N¼26) GC 200 1.4 (1.7) .41 1.8 (1.1) .10 0.4 (1.0) .68 22.1 (0.6) .00** 1.4 (2.1) .50
GG 280 24.2 (1.7) .01** 3.3 (1.1) .00** 0.9 (1.0) .36 23.1 (0.6) .00** 0.5 (2.0) .80
rs3740390c,d (ref TT, N¼20) CT 192 0.6 (1.9) .73 1.4 (1.3) .27 0.7 (1.2) .53 22.3 (0.7) .00** 0.2 (2.3) .93
CC 293 23.8 (1.9) .05** 3.0 (1.2) .02** 0.8 (1.2) .50 23.4 (0.7) .00** 0.5 (2.3) .82
rs11191453d (ref TC, N¼212) TT 290 23.3 (0.7) .00** 1.8 (0.5) .00** 1.5 (0.5) .00** 21.3 (0.3) .00** 0.7 (0.9) .43
rs10748835 (ref AA, N¼98) GA 251 1.5 (1.0) .12 0.7 (0.6) .27 0.8 (0.6) .19 20.6 (0.4) .10* 0.7 (1.2) .59
GG 151 22.2 (1.1) .04** 1.3 (.7) .07* 0.9 (0.7) .16 21.1 (0.4) .01** 0.1 (1.3) .95
VNTR (ref A2B, N¼127) AB 587 21.6 (0.8) .04** 0.9 (0.5) .09* 0.7 (0.5) .14 0.2 (0.3) .45 0.2 (1.4) .88
aLinear regression model adjusted for age and gender; referent genotype defined as the genotype associated in previous literature with a higher DMAs%.
b,c,dThe pairs of variants shown were in linkage disequilibrium with r2>0.80.
*P< .10,
**P< .05 for coefficients of associations between AS3MT variants and urinary As profiles, results come from multiple linear regression model adjusted for age and gen-
der. Coefficients (SE) were bolded when they reached significance (P< .10).
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FIG. 1. Associations between AS3MT variants and urinary arsenic profiles among subjects with higher versus lower water arsenic (As). †P < .10 ‡P < .05 for differences
in urinary As profiles associated with having non-referent AS3MT variants genotypes compared with referent genotypes, where referent genotypes were defined as
those associated with a higher DMAs% in previous studies. Wild type genotypes, defined based on global genotype frequency reports from the National Center for
Biotechnology Information, were underlined. *Indicates interaction (P < .10) for variant X categorical water iAs (>50 vs50 ppb). Results come from multiple linear
regression models adjusted for age and gender.
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interactions did not reach significance, the magnitude of associ-
ations with polymorphisms in rs10748835 and both the DMAs%
and MAs% were more than 2 times larger among highly
versus more moderately exposed individuals (Figure 1A and B,
Supplementary Appendix Table 4).
In contrast to the stronger associations seen at higher levels
of exposure for these 3 variants, for polymorphisms in
rs17881215 the magnitude of association with both the DMAs%
and MAs% was marginally significantly weaker at higher expo-
sure (P< .10; Figure 1A and B, Supplementary Appendix Tables 3
and 4). There was, however, no difference in the magnitude of
association between polymorphisms in this SNP and the DMAs/
MAs ratio at high versus low levels of exposure.
In models predicting variation in the iAs% and the MAs/iAs
ratio, no significant effect modification by water As was
observed. However, for both outcomes, the magnitude of associa-
tions appeared to vary depending on the level of water As expo-
sure for polymorphisms that included both rs10748835 and
rs17881215, for which interactions reached significance for other
measures (Supplementary Appendix Table 4, Figure 1D and E).
In sensitivity analyses exploring the effects of additionally
adjusting for diabetes (Supplementary Appendix Table 2), or for
BMI, urinary tAs and water As (not shown), there were no mean-
ingful differences in results. False discovery rate adjustment
(Benjamini et al., 2001) of models for each measure of metabo-
lism led to loss of significance for associations with a number of
variants and iAs%, and for the association between variants in
rs3740390 and MAs% among subjects exposed to low levels of
drinking water arsenic. Interactions for models predicting the
DMA/MAs ratio remained significant.
DISCUSSION
Inter-individual variation in urinary measures of iAs metabo-
lism has been associated with the risk of adverse health out-
comes associated with iAs exposure (Kuo et al., 2015; Mendez
et al., 2015; Pierce et al., 2013; Sun et al., 2007), indicating that fac-
tors influencing metabolism may affect susceptibility to dis-
ease. There is growing evidence—including a recent review—
that a number of candidate variants in AS3MT affect iAs metab-
olism (Antonelli et al., 2014; Fu et al., 2014; Gribble et al., 2015;
Pierce et al., 2012; Schlebusch et al., 2015; Wood et al., 2006). At
present, evidence on the consistency with which these variants
relate to markers of metabolism across populations is limited
FIG. 1. Continued
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and mixed, perhaps in part due to the small sample size and
modest power in most previous studies (N< 300) (Drobna et al.,
2013; Fu et al., 2014). Moreover, although it has been suggested
that the extent to which some variants influence iAs metabo-
lism might be stronger among subjects more highly exposed to
iAs (Pierce et al., 2013), to our knowledge, studies have yet to for-
mally explore such heterogeneity. In this study, we aimed to
confirm relationships between 7 candidate AS3MT variants and
urinary markers of iAs metabolism (Antonelli et al., 2014; Beebe-
Dimmer et al., 2012; Drobna et al., 2013; Engstrom et al., 2011,
2015; Hernandez et al., 2014; Hernandez-Zavala et al., 2008;
Hwang et al., 2010; Lindberg et al., 2007; Sampayo-Reyes et al.,
2010; Valenzuela et al., 2009; Wood et al., 2006), and examine the
extent to which these associations may vary depending on the
level of exposure to drinking water As.
In this study, genotypes associated with a higher DMAs% in
previous studies were consistently associated with significantly
higher DMAs%, DMAs/MAs and lower MAs%; almost all associa-
tions were at least marginally significant at P< .10. Reference
genotypes also tended to be associated with a lower iAs%, though
these relationships were largely not significant. However, associ-
ations with the ratio of MAs to iAs, which has been used as an
indicator of the efficiency of the first methylation step, were con-
sistently non-significant, and varied considerably in terms of
direction and magnitude.
We found significant interactions between 4 of the 7 candi-
date AS3MT variants and concentrations of As in drinking
water. Three SNPs (rs3740393, rs3740390, and rs10748835) had
somewhat stronger associations with indicators of iAs metabo-
lism among individuals exposed to higher versus lower levels of
As in drinking water, with significant differences in the magni-
tude of association for the DMAs/MAs ratio. In contrast, one
SNP (rs17881215) was more strongly associated with 2 markers
of iAs metabolism—the DMAs% and MAs%—among partici-
pants with lower rather than with higher exposure. This sug-
gests that the genetic variants most influential for aspects of
iAs metabolism may vary across populations, depending on
prevailing levels of exposure. This finding also suggests the pos-
sibility that the variants most influential for modifying health
risks may differ in more highly exposed populations than in set-
tings with low exposure. Though earlier studies, to the best of
our knowledge, have not formally examined whether the degree
of exposure to iAs may modify the influence of AS3MT variants
on iAs metabolism, prior literature has suggested that patterns
of metabolism may vary by level of exposure (Ahsan et al., 2007;
Kile et al., 2009; Lindberg et al., 2008; Styblo et al., 1999; Tseng,
2009). Several studies have suggested that at exposures exceed-
ing 50 ppb, there may be an increase in the MAs% in urine and
decrease in DMAs%, perhaps due to saturated capacity for the
secondary methylation step or the inhibition of AS3MT activity
by high levels of iAs (Kile et al., 2009; Lindberg et al., 2008). At
these higher exposures, genetic variants may be either more, or
less, influential on iAs metabolism. However, in our sample, we
did not observe meaningful differences in urinary As profiles
between groups exposed to higher (50 ppb) versus lower con-
centrations of water As in our study. The median (25th and 75th
percentile) for more versus less exposed groups were 77.2%
(71.4%, 81.8%) versus 76.5% (70.9%, 81.2%), 14.0% (11.1%, 17.4%)
versus 13.6% (10.9%. 17.4%), and 5.4 (4.2, 7.3) versus 5.6 (4.2, 7.4)
for DMAs%, MAs%, and DMAs/MAs accordingly (Kruskall-Wallis
P> .10 for all pairwise comparisons).
Interactions between AS3MT variants and levels of exposure
(ie, water iAs) did not depend on the magnitude of the associa-
tion between those variants and urinary iAs profiles in the
overall population. For example, in the population as a whole,
polymorphisms in rs10748835 were much more weakly associ-
ated with urinary iAs metabolites than those in rs3740393.
However, there were significant differences in the magnitude of
association with the DMAs/MAs ratio among participants with
high versus low exposure for both variants.
In our analyses, the referent genotype, defined as the one
previously associated with a higher DMAs%—and postulated to
be associated as well with a higher DMAs/MAs, lower MAs%,
and lower iAs%—was not always the major (ie, most frequent)
genotype in our sample. Indeed, the postulated beneficial refer-
ent genotype was the major genotype only for rs11191439 and
rs17881215, the SNPs with the strongest magnitude of associa-
tion with methylation indicators in our sample (see Table 2).
It is unclear what the implications of the AS3MT variant-iAs
metabolism associations are for health of iAs-exposed individu-
als. Based on previous literature, the relevance of a high versus
low DMAs%, MAs%, or DMAs/MAs ratio for health risks is uncer-
tain, and may depend on the level of exposure. Several studies
in high exposure settings have found a high MAs% to be associ-
ated with increased risk of cancer and other health outcomes,
including cardiovascular diseases and diabetes (Chen et al.,
2005; Chung et al., 2009a,b; Lindberg et al., 2008). However,
numerous studies in settings with more moderate exposure
have reported a higher DMAs% to be associated with increased
risk of diabetes and other cardiometabolic outcomes (Chen
et al., 2013; Del Razo et al., 2011; Mendez et al., 2015; Nizam et al.,
2013). The conflicting results for the associations between uri-
nary iAs methylation profiles and health outcomes may be due
to differences in the distribution of trivalent and pentavalent
methylated metabolites (MAsIII vs MAsV; DMAsIII vs DMAsV)
which exhibit different toxicities in laboratory models (Chung
et al., 2009; Del Razo et al., 2011; Kligerman and Tennant, 2007;
Nizam et al., 2013; Petrick et al., 2000; Schwerdtle et al., 2003;
Styblo et al., 2000; Tseng, 2007). However, differentiating
between the trivalent and pentavalent As species in urine is
technically challenging and is rarely implemented in population
studies (Valenzuela et al., 2005). Therefore, analyses performed
in most population studies, including this study, are typically
limited to measurements of total iAs, MAs, and DMAs, and the
percentages and ratios of these metabolites in urine.
Though a considerable literature indicates that inter-
individual variation in the capacity to metabolize iAs is associ-
ated with diverse health risks, including cancer, diabetes, cardi-
ovascular disease, and skin lesions (Chen et al., 2013; Gribble
et al., 2014; Huang et al., 2007; Karagas et al., 1998; Kuo et al., 2015;
Lesseur et al., 2012; Mendez et al., 2015; Pierce et al., 2013; Tseng,
2007), less is known about the health effects of variants in
AS3MT that influence metabolism. Previous studies of candi-
date SNPs in AS3MT, which strongly influences arsenic metabo-
lism, have also reported significant associations between
arsenic-related health outcomes and the variants in the SNPs
we found to most strongly relate to lower DMAs% and higher
MAs%, rs11191439 and rs17881215. In a separate Mexican popu-
lation with moderately high levels of drinking water arsenic, C
versus T alleles in rs11191439 [M287T] were associated with sig-
nificantly higher levels of trivalent DMAs in urine and increases
in 2-h and fasting glucose (Drobna et al., 2013), as well as with
increased odds of skin lesions (Valenzuela et al., 2009). Variants
in this SNP have also been associated with increases in cytoge-
netic damage in subjects occupationally exposed to arsenic
(Hernandez et al., 2014). However, in a U.S. population with low
exposure (only 2.5% of the sample had>50 ppb drinking water
As), associations between rs11191439 variants and bladder
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cancer were null (Karagas et al., 1998; Lesseur et al., 2012).
Similarly, C versus G alleles in rs17881215 [G4965C] were associ-
ated with increases in trivalent DMAs and higher fasting and 2-
h glucose (Drobna et al., 2013). For rs3740393 (G vs C), rs3740390
(C vs T), and/or rs10748835 (G vs A)—the 3 variants for which we
found significant interactions with exposure in our analysis of
methylation patterns—there were null associations with the
outcomes under study: glucose levels (Drobna et al., 2013), skin
lesions (Valenzuela et al., 2009), or bladder cancer (Lesseur et al.,
2012). These studies did not examine interactions between
SNPs and arsenic exposure. A recent study in Bangladesh
(Pierce et al., 2013) found evidence of such an interaction.
Variants in rs9527 (P< .05), the AS3MT SNP that was associated
with DMAs% and MAs% in urine, were also associated with
increased odds of skin lesions, but only among individuals in
the highest tertile of water arsenic exposure (>87 ppb). Though
mechanisms remain to be fully elucidated, a study in a U.S. pop-
ulation reported differential methylation of the AS3MT pro-
moter depending on arsenic exposure (Gribble et al., 2014).
This study was conducted in the Chihuahua area of Mexico,
with moderately elevated levels of iAs in drinking water
(median concentration of 48.6 ppb). Many previous studies have
been conducted in areas with substantially higher exposure
(Maull et al., 2012) (eg, water iAs exposure level for studies done
in Bangladesh is likely to be between 100 and 200 ppb (Ahsan
et al., 2007; Chen et al., 2013; Farzan et al., 2015; Lindberg et al.,
2008)). Thus there is uncertainty regarding the health effects of
more moderate levels of iAs exposure, and the influence of
genetic polymorphisms on iAs metabolism and toxicity, in
areas with moderate exposure, which are more typical popula-
tion exposures around the world. The range of exposure in this
Chihuahua cohort—with nearly 50% of subjects at levels below
50 ppb—enabled us to analyze interactions between AS3MT var-
iants in the moderate range of water As exposure at which
some studies have suggested iAs metabolism may shift (Kile
et al., 2009; Lindberg et al., 2008).
A limitation of this study is that, although the sample size
was larger than in many previous studies(Drobna et al., 2013;
Engstrom et al., 2011; Fu et al., 2014; Lindberg et al., 2007;
Valenzuela et al., 2009), we had small cell sizes for genotypes of
several candidate AS3MT variants, particularly in analyses
stratified by water As. The small cell sizes may have reduced
our power to detect interactions between level of exposure and
methylation profiles for those variants.
CONCLUSION
In this study, 7 AS3MT variants which may play a role in iAs
metabolism were examined based on results of previous stud-
ies. The patterns of association between markers of iAs metabo-
lism and these variants were highly consistent with those
reported in previous studies, confirming that these variants are
in part responsible for the inter-individual differences in uri-
nary profiles of iAs metabolites. We found that specific geno-
types in 5 SNPs, rs17881215, rs3740393, rs3740390, rs11191439,
and rs11191453, were associated with significantly higher
DMAs% and lower MAs% in urine. Polymorphisms in these
SNPs, along with rs10748835, were also associated with the
DMAs/MAs ratio.
Our results also suggested that the role of several of these
AS3MT variants in iAs metabolism may differ among populations
with different levels of iAs exposure. Three SNPs, rs3740393,
rs3740390, and rs10748835, appeared to have significantly more
potent effects, based on associations with larger decreases in the
DMAs/MAs ratio, among subjects highly exposed to As in drink-
ing water (>50 ppb). In contrast, rs17881215 had significantly
more potent effects among subjects with lower water As levels.
Since measures of iAs metabolism have been associated with
risk of adverse health outcomes, these findings suggest that var-
iants in AS3MT may influence susceptibility to health effects of
iAs exposure, and that the role of these variants may depend on
the level of iAs exposure. However, given that toxicity of iAs
metabolites varies by oxidation status (Del Razo et al., 2011;
Kligerman and Tennant, 2007; Nizam et al., 2013; Petrick et al.,
2000; Schwerdtle et al., 2003; Styblo et al., 2000; Tseng, 2007), fur-
ther research focusing on whether and how these variants relate
to the distribution of trivalent and pentavalent metabolites is
needed to better clarify the influence of AS3MT polymorphism on
iAs methylation profiles, and on health outcomes.
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